DSRV.io · Enforcement-informed quality intelligence
DSRVDSRV.io
Browse by regulation3 articles · 1 high · 2 moderate

21 CFR 211.166

Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.166: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set
In brief
What has FDA cited under 21 CFR 211.166?
3 DSRV articles cite 21 CFR 211.166. Enforcement cases behind them: FDA Warning Letter CMS Case 723059 to Sato Pharmaceutical Co., Ltd., May 18, 2026; ICH Q1A(R2) stability data expectations and FDA review practice for retest period and shelf-life justifications under 21 CFR Part 211; Recurring FDA stability program observations under 21 CFR §211.166 and excursion-handling expectations informed by ICH Q1A(R2). Inspection exposure across them: 1 high, 2 moderate.
What does DSRV recommend for 21 CFR 211.166?
From the newest article (Media-Fill Failure Is Not the Root Cause. It Is the Alarm Bell.): A media-fill failure is the alarm bell, not the root cause: after repeated failures FDA stops evaluating individual events and starts evaluating whether the quality unit ever accurately diagnosed the design failure driving them. DSRV is decision support, not legal advice; verify against the official source each article names.
  1. 5 min readHigh exposurecited as a tag

    Media-Fill Failure Is Not the Root Cause. It Is the Alarm Bell.

    FDA’s May 18, 2026 warning letter to Sato Pharmaceutical describes six consecutive media-fill failures as a quality-system credibility collapse. The inspection-readiness lessons span ISO 5/RABS design, smoke studies, contamination prevention, and systemic CAPA, and they generalize far beyond Sato.

    Case
    FDA Warning Letter CMS Case 723059 to Sato Pharmaceutical Co., Ltd., May 18, 2026.
    DSRV take
    A media-fill failure is the alarm bell, not the root cause: after repeated failures FDA stops evaluating individual events and starts evaluating whether the quality unit ever accurately diagnosed the design failure driving them.
  2. 8 min readModerate exposurecited as a tag

    What Evidence Supports a Stability Justification?

    A shelf-life claim is only as strong as the stability evidence behind it. We outline what ICH Q1A(R2)-aligned data, trend analysis, and supporting studies actually substantiate a justification.

    Case
    ICH Q1A(R2) stability data expectations and FDA review practice for retest period and shelf-life justifications under 21 CFR Part 211.
    DSRV take
    A shelf-life justification is an evidence argument - long-term data, demonstrated stability-indicating methods, and trend analysis, not a stack of individually passing results.
  3. 7 min readModerate exposure

    When Stability Data Gaps Become Inspection Exposure

    Not every stability gap is equal. A missing time point, an unmanaged excursion, or an under-powered trend can quietly become an inspection finding. Here is how to triage which gaps create real exposure.

    Case
    Recurring FDA stability program observations under 21 CFR §211.166 and excursion-handling expectations informed by ICH Q1A(R2).
    DSRV take
    The inspection question is never whether gaps exist - it is whether each gap weakens the shelf-life justification and whether you documented how you managed it.
Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under 21 CFR 211.166. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about 21 CFR 211.166

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.